Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971969 · ClinicalTrials.gov registry record
Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
A clinical trial of Hemophilia B, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 6
- Enrollment target
- 5
- Study locations
NCT02971969: Completed study of Hemophilia B, sponsored by Ultragenyx Pharmaceutical.
NCT02971969 is a study of Hemophilia B that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 6 participants, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02971969, a study of Hemophilia B, has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
- 5
- Study locations
Study Summary
A long-term follow-up study to evaluate the safety, tolerability, and efficacy of DTX101 in adult males with moderate/severe to severe hemophilia B.
Conditions Studied
Study Locations (5)
Arkansas
- Arkansas Children's Hospital - Little Rock
Florida
- UF CRC - Clinical Research Center - Gainesville
Michigan
- University of Michigan Hospital and Health Systems - Ann Arbor
Hampshire
- Haemophilia, Haemostasis & Thrombosis Centre - Basingstoke
Other
- Manchester Haemophilia Comprehensive Care Center - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-01 |
| Est. Completion | 2021-11-06 |
What the finished NCT02971969 record still lists
NCT02971969 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Hemophilia B appearing as the primary indexed condition, and to 0 interventions.
NCT02971969 lists 5 locations in 5 states (Arkansas, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT02971969 about?
NCT02971969 is a clinical study titled "Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B". A long-term follow-up study to evaluate the safety, tolerability, and efficacy of DTX101 in adult males with moderate/severe to severe hemophilia B.
What is the current status of trial NCT02971969?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2017-01. Estimated completion is 2021-11-06.
What conditions does trial NCT02971969 study?
This clinical trial studies the following conditions: Hemophilia B.
Who is sponsoring clinical trial NCT02971969?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02971969 being conducted?
This trial has 5 study locations across Arkansas, Florida, Michigan, Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02971969's enrollment target sits among peer trials
6 21st of 20 the lowest of 20 other Hemophilia B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
RECRUITING · Phase 1
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RECRUITING · Phase 3
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia